Mechanochemical consequences of myopathy‐linked mutations in Tpm2.2 on striated muscle contractility
The FASEB Journal · 2024
DOI: 10.1096/fj.202301604r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Recep Küçükdogru und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Cell Biology, Faculty of Biological Sciences, Kazimierz Wielki University, Bydgoszcz, Poland. Hauptthemen laut MEDLINE: Muscular Diseases, Tropomyosin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Polish Minister of Education and Science under the program "Regional Initiative of Excellence" in 2019-2023.
Abstract (Originalsprache)
Tropomyosin (Tpm) is an actin‐binding protein central to muscle contraction regulation. The Tpm sequence consists of periodic repeats corresponding to seven actin‐binding sites, further divided in two functionally distinct halves. To clarify the importance of the first and second halves of the actin‐binding periods in regulating the interaction of myosin with actin, we introduced hypercontractile mutations D20H, E181K located in the N‐terminal halves of periods 1 and 5 and hypocontractile mutations E41K, N202K located in the C‐terminal halves of periods 1 and 5 of the skeletal muscle Tpm isoform Tpm2.2. Wild‐type and mutant Tpms displayed similar actin‐binding properties, however, as revealed by FRET experiments, the hypercontractile mutations affected the binding geometry and orientation of Tpm2.2 on actin, causing a stimulation of myosin motor performance. Contrary, the hypocontractile mutations led to an inhibition of both, actin activation of the myosin ATPase and motor activity, that was more pronounced than with wild‐type Tpm2.2. Single ATP turnover kinetic experiments indicate that the introduced mutations have opposite effects on product release kinetics. While the hypercontractile Tpm2.2 mutants accelerated product release, the hypocontractile mutants decelerated product release from myosin, thus having either an activating or inhibitory influence on myosin motor performance, which agrees with the muscle disease phenotypes caused by these mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Cell Biology, Faculty of Biological Sciences, Kazimierz Wielki University, Bydgoszcz, Poland.
- Cellular Biophysics, Institute for Biophysical Chemistry, Hannover Medical School, Hannover, Germany.
- Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
ORCID-Profile: Recep Küçükdogru, Peter Franz, Remigiusz Worch, Katarzyna Robaszkiewicz, Małgorzata Siatkowska, Georgios Tsiavaliaris, Joanna Moraczewska
Förderung
- the Polish Minister of Education and Science under the program "Regional Initiative of Excellence" in 2019-2023
Zitieren
APA
Küçükdogru, R., Franz, P., Worch, R., Robaszkiewicz, K., Siatkowska, M., Tsiavaliaris, G., & Moraczewska, J. (2024). Mechanochemical consequences of myopathy‐linked mutations in Tpm2.2 on striated muscle contractility. The FASEB Journal. https://doi.org/10.1096/fj.202301604r
Vancouver
Küçükdogru R, Franz P, Worch R, Robaszkiewicz K, Siatkowska M, Tsiavaliaris G, et al. Mechanochemical consequences of myopathy‐linked mutations in Tpm2.2 on striated muscle contractility. The FASEB Journal. 2024. doi:10.1096/fj.202301604r
BibTeX
@article{Kkdogru2024,
author = {Küçükdogru, Recep and Franz, Peter and Worch, Remigiusz and Robaszkiewicz, Katarzyna and Siatkowska, Małgorzata and Tsiavaliaris, Georgios and Moraczewska, Joanna},
title = {Mechanochemical consequences of myopathy‐linked mutations in Tpm2.2 on striated muscle contractility},
journal = {The FASEB Journal},
year = {2024},
doi = {10.1096/fj.202301604r}
}
EUVIMED